Breathe Better with Spiromatics

At Spiromatics, we deliver advanced, reproducible imaging and functional biomarkers that enhance patient selection, endpoint sensitivity, and disease progression modeling in clinical trials. Our AI-driven analytics transform lung CT and spirometry data into reliable, quantitative measures that reflect therapeutic effects more precisely than conventional metrics. By partnering with us, pharmaceutical companies gain robust tools for evaluating drug efficacy, optimizing trial design, and accelerating the development of novel respiratory therapies. 

For medical device innovators, Spiromatics offers the analytical backbone for validation, performance monitoring, and regulatory support. Our quantitative imaging and spirometry biomarkers provide objective endpoints to assess device impact on lung structure and function, ensuring reliable evidence of clinical benefit. We collaborate closely with device developers to integrate our biomarkers into clinical studies, usability testing, and post-market evaluation, helping translate technical innovation into measurable improvements in patient outcomes. 

Spiromatics actively collaborates with academic and research institutions to push the boundaries of lung disease characterization. Our expertise in AI, image processing, and computational physiology supports projects ranging from novel biomarker discovery to large-scale population studies. By partnering with us, academic teams gain access to cutting-edge analytical tools and collaborative research opportunities that advance understanding of airway disease mechanisms and enable innovation at the intersection of engineering and medicine.